세계의 효소보충요법(ERT) 시장 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2031)

Enzyme Replacement Therapy Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

US $ 4,995 ￦ 6,970,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,179,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,853,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

주요 인사이트

• 효소보충요법(ERT) 시장 규모(2024년) : 110억 달러
• 시장 규모 예측(2031년) : 177억 달러
• 세계 시장 성장률(2024-2031년) : CAGR 7.1%

시장 성장 촉진요인 :

세계 효소보충요법(ERT) 시장은 고셔병, 파브리병, 폼페병과 같은 희귀 유전질환의 유병률 증가, 진단율 향상으로 인한 치료 수요 증가 등의 주요 요인에 의해 주도되고 있습니다. 생명공학, 특히 재조합 DNA 기술의 발전으로 매우 효과적이고 표적화된 치료법 개발이 가능해졌습니다. 또한, 정부의 재정 지원과 상환 정책으로 치료 접근성을 높이고, 교육 캠페인과 환자 지원 단체의 인식 개선이 진단율과 치료법 보급을 촉진하고 있습니다.

시장 성장 억제요인 :

효소보충요법(ERT) 시장은 큰 잠재력을 가지고 있지만, 주목할 만한 문제에 직면해 있습니다. 연구, 제조 및 유통 관련 비용을 포함한 높은 치료비용은 중저소득층에서 ERT의 사용을 제한하고 있습니다. 또한, 생물학적 활성 효소에 필요한 복잡한 제조 공정은 엄격한 규제 준수를 요구하기 때문에 상용화가 지연되는 경우가 많습니다. 또한, 일부 환자에서 부작용으로 면역반응이 나타나기 때문에 세심한 모니터링과 조정이 필요하며, 이는 보다 광범위한 시장 도입을 방해할 수 있습니다.

시장 기회 :

효소보충요법(ERT) 시장은 연구 발전과 전략적 제휴에 힘입어 풍부한 기회를 보이고 있습니다. 아시아태평양 및 라틴아메리카 등 신흥 시장은 인식 개선과 의료 인프라 개선으로 인해 큰 성장 잠재력을 가지고 있습니다. 유전체 연구와 바이오마커 분석으로 촉진되는 개인 맞춤형 의료의 부상으로 효능을 높이기 위한 맞춤형 ERT 솔루션이 가능해졌습니다. 제약사, 연구기관 및 지원 단체 간의 전략적 파트너십은 기술 혁신을 가속화하고 효소 치료의 적용 범위를 확장하고 있습니다. 또한, 경구용 효소 제제 및 유전자 치료의 개발은 기존의 정맥 내 치료를 대체할 수 있는 혁신적인 변화를 보여주고 있습니다.

세계의 효소보충요법(ERT) 시장을 조사했으며, 시장 정의와 개요, 시장 성장 촉진요인 및 억제요인, 각종 동향, 시장 기회와 과제, 시장 규모(금액 및 일부 수량) 추이와 예측, 각종 부문별/지역별/주요 국가별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 범위와 정의
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 과제
  • 주요 동향
• 거시경제 요인
  • 세계의 부문별 전망
  • 세계의 GDP 성장 전망
  • 세계의 의료비 지출 전망
• COVID-19의 영향 분석
• 예측 요인 : 관련성과 영향

제3장 부가가치 인사이트

• 대상 질환별 채택 분석
• 기술 평가
• 규제 상황
• 밸류체인 분석
• 주요 거래와 합병
• PESTLE 분석
• Porter의 Five Forces 분석

제4장 가격 동향 분석

• 주요 하이라이트
• 제품 가격에 영향을 미치는 주요 요인
• 대상 질환별 가격 분석
• 지역별 가격과 제품 선호

제5장 세계의 효소보충요법 시장 전망 : 추이와 예측

• 주요 하이라이트
  • 시장 규모 예측
  • 시장 규모와 전년대비 성장률
  • 매출 기회
• 시장 규모 분석과 예측
• 세계의 효소보충요법 시장 전망 : 대상 질환별
  • 시장 규모 추이
  • 시장 규모 예측
• 시장의 매력 분석 : 대상 질환별
• 세계의 효소보충요법 시장 전망 : 투여 경로별
  • 시장 규모 추이
  • 시장 규모 예측
• 시장의 매력 분석 : 투여 경로별
• 세계의 효소보충요법 시장 전망 : 유통 채널별
  • 시장 규모 추이
  • 시장 규모 예측
• 시장의 매력 분석 : 유통 채널별

제6장 세계의 효소보충요법 시장 전망 : 지역별

• 주요 하이라이트
• 시장 규모 추이
• 시장 규모 예측
  • 북미
  • 유럽
  • 동아시아
  • 남아시아 및 오세아니아
  • 라틴아메리카
  • 중동 및 아프리카
• 시장의 매력 분석 : 지역

제7장 북미의 효소보충요법(ERT) 시장 전망 : 추이와 예측

• 주요 하이라이트
• 가격 분석
• 시장 규모 추이
  • 국가별
  • 대상 질환별
  • 투여 경로별
  • 유통 채널별
• 시장 규모 분석과 예측 : 국가별
  • 미국
  • 캐나다
• 시장 규모 분석과 예측 : 대상 질환별
  • 파브리병
  • 고셔병
  • 뮤코다당증(MPS)
  • 폼페병
  • 리소좀 산성 리파아제 결손증
  • 기타
• 시장 규모 분석과 예측 : 투여 경로별
  • 경구 효소보충요법
  • 주사 효소보충요법
• 시장 규모 분석과 예측 : 유통 채널별
  • 병원 약국
  • 전문 치료제
  • 소매 약국
• 시장의 매력 분석

제8장 유럽의 효소보충요법(ERT) 시장 전망 : 추이와 예측

• 주요 하이라이트
• 가격 분석
• 시장 규모 추이
• 시장 규모 분석과 예측 : 국가별
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 러시아
  • 터키
  • 기타
• 시장 규모 분석과 예측 : 대상 질환별
• 시장 규모 분석과 예측 : 투여 경로별
• 시장 규모 분석과 예측 : 유통 채널별
• 시장의 매력 분석

제9장 동아시아의 효소보충요법(ERT) 시장 전망 : 추이와 예측

• 주요 하이라이트
• 가격 분석
• 시장 규모 추이
• 시장 규모 분석과 예측 : 국가별
  • 중국
  • 일본
  • 한국
• 시장 규모 분석과 예측 : 대상 질환별
• 시장 규모 분석과 예측 : 투여 경로별
• 시장 규모 분석과 예측 : 유통 채널별
• 시장의 매력 분석

제10장 남아시아 및 오세아니아의 효소보충요법(ERT) 시장 전망 : 추이와 예측

• 주요 하이라이트
• 가격 분석
• 시장 규모 추이
• 시장 규모 분석과 예측 : 국가별
  • 인도
  • 동남아시아
  • 호주
  • 기타
• 시장 규모 분석과 예측 : 대상 질환별
• 시장 규모 분석과 예측 : 투여 경로별
• 시장 규모 분석과 예측 : 유통 채널별
• 시장의 매력 분석

제11장 라틴아메리카의 효소보충요법(ERT) 시장 전망 : 추이와 예측

• 주요 하이라이트
• 가격 분석
• 시장 규모 추이
• 시장 규모 분석과 예측 : 국가별
  • 브라질
  • 멕시코
  • 기타
• 시장 규모 분석과 예측 : 대상 질환별
• 시장 규모 분석과 예측 : 투여 경로별
• 시장 규모 분석과 예측 : 유통 채널별
• 시장의 매력 분석

제12장 중동 및 아프리카의 효소보충요법(ERT) 시장 전망 : 추이와 예측

• 주요 하이라이트
• 가격 분석
• 시장 규모 추이
• 시장 규모 분석과 예측 : 국가별
  • GCC 국가
  • 이집트
  • 남아프리카공화국
  • 북아프리카
  • 기타
• 시장 규모 분석과 예측 : 대상 질환별
• 시장 규모 분석과 예측 : 투여 경로별
• 시장 규모 분석과 예측 : 유통 채널별
• 시장의 매력 분석

제13장 경쟁 구도

• 시장 점유율 분석
• 시장 구조
• 기업 개요(상세 : 개요, 재무, 전략, 최근 동향)
  • Sanofi Genzyme
  • Shire(now part of Takeda Pharmaceuticals)
  • BioMarin Pharmaceutical Inc.
  • Amicus Therapeutics
  • Alexion Pharmaceuticals
  • Ultragenyx Pharmaceutical Inc.
  • Sarepta Therapeutics
  • Biomarin
  • Genzyme(now part of Sanofi)
  • Takeda Pharmaceuticals
  • Pfizer Inc.
  • AbbVie Inc.
  • Vertex Pharmaceuticals
  • Sangamo Therapeutics
  • Regeneron Pharmaceuticals Inc.
  • Spark Therapeutics(now part of Roche)
  • Orchard Therapeutics
  • Novartis AG
  • CSL Behring
  • Audentes Therapeutics

제14장 부록

LSH

영문 목차

영문목차

Persistence Market Research presents an in-depth analysis of the Enzyme Replacement Therapy (ERT) Market, offering insights into its intricate dynamics and future trajectory. From market trends to growth catalysts, impediments, and emerging patterns, this report furnishes invaluable statistics and projections spanning from 2024 to 2031.

Key Insights:

• Enzyme Replacement Therapy Market Size (2024): USD 11 Bn
• Projected Market Value (2031): USD 17.7 Bn
• Global Market Growth Rate (CAGR 2024 to 2031): 7.1%

Enzyme Replacement Therapy Market - Report Scope:

The Enzyme Replacement Therapy (ERT) Market encompasses various applications across healthcare sectors such as genetic disorders, lysosomal storage diseases, and metabolic disorders. This therapy involves the replacement of deficient or absent enzymes with recombinant or synthetic alternatives, significantly improving patients' quality of life. The market caters to a wide range of end-users, including pharmaceutical companies, healthcare providers, and specialized treatment centers, offering solutions for managing chronic conditions. Market growth is driven by factors such as rising prevalence of rare diseases, increasing healthcare expenditure, and advancements in biotechnology.

Market Growth Drivers:

The global Enzyme Replacement Therapy (ERT) Market is driven by key factors, including the rising prevalence of rare genetic disorders like Gaucher's disease, Fabry disease, and Pompe disease, spurred by improved diagnosis rates that boost therapy demand. Advancements in biotechnology, particularly in recombinant DNA technology, have enabled the development of highly effective and targeted treatments. Additionally, government support through financial assistance and reimbursement policies has expanded therapy accessibility, while growing awareness fueled by educational campaigns and patient advocacy groups continues to enhance diagnosis rates and treatment adoption.

Market Restraints:

While the Enzyme Replacement Therapy (ERT) Market demonstrates significant potential, it faces notable challenges. High treatment costs, including expenses related to research, manufacturing, and distribution, limit accessibility in low- and middle-income regions. Additionally, the complex manufacturing processes required for biologically active enzymes demand stringent regulatory compliance, often slowing down commercialization. Furthermore, adverse immune reactions in some patients necessitate careful monitoring and adjustments, which can hinder broader market adoption.

Market Opportunities:

The Enzyme Replacement Therapy (ERT) Market is ripe with opportunities, propelled by advancements in research and strategic collaborations. Emerging markets like Asia-Pacific and Latin America offer significant growth potential, driven by increasing awareness and improving healthcare infrastructure. The rise of personalized medicine, facilitated by genomic research and biomarker analysis, is enabling tailored ERT solutions for enhanced efficacy. Strategic partnerships among pharmaceutical companies, research institutions, and advocacy groups are accelerating innovation and expanding the reach of enzyme therapies. Moreover, the development of oral enzyme formulations and gene therapies marks a transformative shift, potentially replacing traditional intravenous treatments.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the Enzyme Replacement Therapy Market globally?
• How are technological advancements and innovative delivery systems shaping the evolution of enzyme therapies?
• What are the challenges and opportunities facing market participants in the ERT segment?
• Which therapeutic areas and geographic regions offer the highest growth potential for enzyme replacement therapy manufacturers?
• What strategies are leading companies employing to differentiate their offerings and capture market share in the competitive landscape?

Competitive Intelligence and Business Strategy:

Leading players in the global Enzyme Replacement Therapy Market are prioritizing innovation, strategic partnerships, and market expansion to secure a competitive edge. Companies are investing heavily in research and development to improve the efficacy and safety of enzyme therapies. Collaboration with academic institutions and patient advocacy organizations facilitates access to cutting-edge research and fosters community support.

Additionally, manufacturers are focusing on patient-centric initiatives, such as affordability programs and educational campaigns, to increase awareness and adoption of enzyme replacement therapies. Emphasis on quality assurance, regulatory compliance, and post-marketing surveillance enhances trust and long-term relationships with healthcare providers and patients.

Key Companies Profiled:

• Sanofi S.A.
• Pfizer Inc.
• Shire (a Takeda company)
• Biomarin Pharmaceutical Inc.
• Alexion Pharmaceuticals, Inc.
• AbbVie Inc.
• Amicus Therapeutics, Inc.
• Roche Holding AG
• CSL Behring
• Horizon Therapeutics Plc
• Genzyme Corporation

Enzyme Replacement Therapy Market Research Segmentation:

By Therapeutic Area:

• Lysosomal Storage Disorders
• Gaucher Disease
• Fabry Disease
• Pompe Disease
• Mucopolysaccharidosis
• Metabolic Disorders
• Others

By Route of Administration:

• Intravenous
• Oral
• Others

By End-User:

• Hospitals
• Specialty Clinics
• Research Institutes

By Region

North America

Latin America

Europe

South Asia and Oceania

East Asia

Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Enzyme Replacement Therapy Market Snapshot, 2024 and 2031
• 1.2. Market Opportunity Assessment, 2024 - 2031, US$ Bn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
  • 2.3.3. Global Healthcare Spending Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Therapeutic Conditions Adoption Analysis
• 3.2. Technology Assessment
• 3.3. Regulatory Landscape
• 3.4. Value Chain Analysis
• 3.5. Key Deals and Mergers
• 3.6. PESTLE Analysis
• 3.7. Porter's Five Force Analysis

4. Price Trend Analysis, 2019 - 2031

• 4.1. Key Highlights
• 4.2. Key Factors Impacting Product Prices
• 4.3. Pricing Analysis, By Therapeutic Conditions
• 4.4. Regional Prices and Product Preferences

5. Global Enzyme Replacement Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

• 5.1. Key Highlights
  • 5.1.1. Market Volume (Units) Projections
  • 5.1.2. Market Size (US$ Bn) and Volume (Units) and Y-o-Y Growth
  • 5.1.3. Absolute $ Opportunity
• 5.2. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast
  • 5.2.1. Historical Market Size (US$ Bn) and Volume (Units) Analysis, 2019 - 2023
  • 5.2.2. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, 2023-2031
• 5.3. Global Enzyme Replacement Therapy Market Outlook: Therapeutic Conditions
  • 5.3.1. Introduction / Key Findings
  • 5.3.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Therapeutic Conditions, 2019 - 2023
  • 5.3.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapeutic Conditions, 2024 - 2031
    • 5.3.3.1. Fabry Disease
    • 5.3.3.2. Gaucher Disease
    • 5.3.3.3. Mucopolysaccharidosis (MPS)
      • 5.3.3.3.1. MPS I (Hurler Syndrome)
      • 5.3.3.3.2. MPS II (Hunter Syndrome)
      • 5.3.3.3.3. MPS IVA (Morquio Syndrome, Type A)
      • 5.3.3.3.4. MPS VI (Maroteaux-Lamy Syndrome)
      • 5.3.3.3.5. MPS VII (Sly Syndrome)
    • 5.3.3.4. Pompe Disease
    • 5.3.3.5. Lysosomal Acid Lipase Deficiency
    • 5.3.3.6. Others
• 5.4. Market Attractiveness Analysis: Therapeutic Conditions
• 5.5. Global Enzyme Replacement Therapy Market Outlook: Route of Administration
  • 5.5.1. Introduction / Key Findings
  • 5.5.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Route of Administration, 2019 - 2023
  • 5.5.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Route of Administration, 2024 - 2031
    • 5.5.3.1. Oral
    • 5.5.3.2. Injectable
• 5.6. Market Attractiveness Analysis: Route of Administration
• 5.7. Global Enzyme Replacement Therapy Market Outlook: Distribution Channel
  • 5.7.1. Introduction / Key Findings
  • 5.7.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Distribution Channel, 2019 - 2023
  • 5.7.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Distribution Channel, 2024 - 2031
    • 5.7.3.1. Hospital Pharmacies
    • 5.7.3.2. Specialty Treatment Pharmacies
    • 5.7.3.3. Retail Pharmacies
• 5.8. Market Attractiveness Analysis: Distribution Channel

6. Global Enzyme Replacement Therapy Market Outlook: Region

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Region, 2019 - 2023
• 6.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Region, 2024 - 2031
  • 6.3.1. North America
  • 6.3.2. Europe
  • 6.3.3. East Asia
  • 6.3.4. South Asia and Oceania
  • 6.3.5. Latin America
  • 6.3.6. Middle East & Africa
• 6.4. Market Attractiveness Analysis: Region

7. North America Enzyme Replacement Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

• 7.1. Key Highlights
• 7.2. Pricing Analysis
• 7.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019 - 2023
  • 7.3.1. By Country
  • 7.3.2. By Therapeutic Conditions
  • 7.3.3. By Route of Administration
  • 7.3.4. By Distribution Channel
• 7.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Country, 2024 - 2031
  • 7.4.1. U.S.
  • 7.4.2. Canada
• 7.5. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapeutic Conditions, 2024 - 2031
  • 7.5.1. Enzyme Replacement Therapy for Fabry Disease
  • 7.5.2. Enzyme Replacement Therapy for Gaucher Disease
  • 7.5.3. Enzyme Replacement Therapy for Mucopolysaccharidosis (MPS)
  • 7.5.4. Enzyme Replacement Therapy for Pompe Disease
  • 7.5.5. Enzyme Replacement Therapy for Lysosomal Acid Lipase Deficiency
  • 7.5.6. Others
• 7.6. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Route of Administration, 2024 - 2031
  • 7.6.1. Oral Enzyme Replacement Therapy
  • 7.6.2. Injectable Enzyme Replacement Therapy
• 7.7. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Distribution Channel, 2024 - 2031
  • 7.7.1. Hospital Pharmacies
  • 7.7.2. Specialty Treatment Pharmacies
  • 7.7.3. Retail Pharmacies
• 7.8. Market Attractiveness Analysis

8. Europe Enzyme Replacement Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

• 8.1. Key Highlights
• 8.2. Pricing Analysis
• 8.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019 - 2023
  • 8.3.1. By Country
  • 8.3.2. By Therapeutic Conditions
  • 8.3.3. By Route of Administration
  • 8.3.4. By Distribution Channel
• 8.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Country, 2024 - 2031
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. U.K.
  • 8.4.4. Italy
  • 8.4.5. Spain
  • 8.4.6. Russia
  • 8.4.7. Turkey
  • 8.4.8. Rest of Europe
• 8.5. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapeutic Conditions, 2024 - 2031
  • 8.5.1. Enzyme Replacement Therapy for Fabry Disease
  • 8.5.2. Enzyme Replacement Therapy for Gaucher Disease
  • 8.5.3. Enzyme Replacement Therapy for Mucopolysaccharidosis (MPS)
  • 8.5.4. Enzyme Replacement Therapy for Pompe Disease
  • 8.5.5. Enzyme Replacement Therapy for Lysosomal Acid Lipase Deficiency
  • 8.5.6. Others
• 8.6. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Route of Administration, 2024 - 2031
  • 8.6.1. Oral Enzyme Replacement Therapy
  • 8.6.2. Injectable Enzyme Replacement Therapy
• 8.7. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Distribution Channel, 2024 - 2031
  • 8.7.1. Hospital Pharmacies
  • 8.7.2. Specialty Treatment Pharmacies
  • 8.7.3. Retail Pharmacies
• 8.8. Market Attractiveness Analysis

9. East Asia Enzyme Replacement Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

• 9.1. Key Highlights
• 9.2. Pricing Analysis
• 9.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019 - 2023
  • 9.3.1. By Country
  • 9.3.2. By Therapeutic Conditions
  • 9.3.3. By Route of Administration
  • 9.3.4. By Distribution Channel
• 9.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Country, 2024 - 2031
  • 9.4.1. China
  • 9.4.2. Japan
  • 9.4.3. South Korea
• 9.5. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapeutic Conditions, 2024 - 2031
  • 9.5.1. Enzyme Replacement Therapy for Fabry Disease
  • 9.5.2. Enzyme Replacement Therapy for Gaucher Disease
  • 9.5.3. Enzyme Replacement Therapy for Mucopolysaccharidosis (MPS)
  • 9.5.4. Enzyme Replacement Therapy for Pompe Disease
  • 9.5.5. Enzyme Replacement Therapy for Lysosomal Acid Lipase Deficiency
  • 9.5.6. Others
• 9.6. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Route of Administration, 2024 - 2031
  • 9.6.1. Oral Enzyme Replacement Therapy
  • 9.6.2. Injectable Enzyme Replacement Therapy
• 9.7. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Distribution Channel, 2024 - 2031
  • 9.7.1. Hospital Pharmacies
  • 9.7.2. Specialty Treatment Pharmacies
  • 9.7.3. Retail Pharmacies
• 9.8. Market Attractiveness Analysis

10. South Asia & Oceania Enzyme Replacement Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

• 10.1. Key Highlights
• 10.2. Pricing Analysis
• 10.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019 - 2023
  • 10.3.1. By Country
  • 10.3.2. By Therapeutic Conditions
  • 10.3.3. By Route of Administration
  • 10.3.4. By Distribution Channel
• 10.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Country, 2024 - 2031
  • 10.4.1. India
  • 10.4.2. Southeast Asia
  • 10.4.3. ANZ
  • 10.4.4. Rest of South Asia & Oceania
• 10.5. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapeutic Conditions, 2024 - 2031
  • 10.5.1. Enzyme Replacement Therapy for Fabry Disease
  • 10.5.2. Enzyme Replacement Therapy for Gaucher Disease
  • 10.5.3. Enzyme Replacement Therapy for Mucopolysaccharidosis (MPS)
  • 10.5.4. Enzyme Replacement Therapy for Pompe Disease
  • 10.5.5. Enzyme Replacement Therapy for Lysosomal Acid Lipase Deficiency
  • 10.5.6. Others
• 10.6. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Route of Administration, 2024 - 2031
  • 10.6.1. Oral Enzyme Replacement Therapy
  • 10.6.2. Injectable Enzyme Replacement Therapy
• 10.7. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Distribution Channel, 2024 - 2031
  • 10.7.1. Hospital Pharmacies
  • 10.7.2. Specialty Treatment Pharmacies
  • 10.7.3. Retail Pharmacies
• 10.8. Market Attractiveness Analysis

11. Latin America Enzyme Replacement Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

• 11.1. Key Highlights
• 11.2. Pricing Analysis
• 11.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019 - 2023
  • 11.3.1. By Country
  • 11.3.2. By Therapeutic Conditions
  • 11.3.3. By Route of Administration
  • 11.3.4. By Distribution Channel
• 11.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Country, 2024 - 2031
  • 11.4.1. Brazil
  • 11.4.2. Mexico
  • 11.4.3. Rest of Latin America
• 11.5. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapeutic Conditions, 2024 - 2031
  • 11.5.1. Enzyme Replacement Therapy for Fabry Disease
  • 11.5.2. Enzyme Replacement Therapy for Gaucher Disease
  • 11.5.3. Enzyme Replacement Therapy for Mucopolysaccharidosis (MPS)
  • 11.5.4. Enzyme Replacement Therapy for Pompe Disease
  • 11.5.5. Enzyme Replacement Therapy for Lysosomal Acid Lipase Deficiency
  • 11.5.6. Others
• 11.6. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Route of Administration, 2024 - 2031
  • 11.6.1. Oral Enzyme Replacement Therapy
  • 11.6.2. Injectable Enzyme Replacement Therapy
• 11.7. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Distribution Channel, 2024 - 2031
  • 11.7.1. Hospital Pharmacies
  • 11.7.2. Specialty Treatment Pharmacies
  • 11.7.3. Retail Pharmacies
• 11.8. Market Attractiveness Analysis

12. Middle East & Africa Enzyme Replacement Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

• 12.1. Key Highlights
• 12.2. Pricing Analysis
• 12.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019 - 2023
  • 12.3.1. By Country
  • 12.3.2. By Therapeutic Conditions
  • 12.3.3. By Route of Administration
  • 12.3.4. By Distribution Channel
• 12.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Country, 2024 - 2031
  • 12.4.1. GCC Countries
  • 12.4.2. Egypt
  • 12.4.3. South Africa
  • 12.4.4. Northern Africa
  • 12.4.5. Rest of Middle East & Africa
• 12.5. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapeutic Conditions, 2024 - 2031
  • 12.5.1. Enzyme Replacement Therapy for Fabry Disease
  • 12.5.2. Enzyme Replacement Therapy for Gaucher Disease
  • 12.5.3. Enzyme Replacement Therapy for Mucopolysaccharidosis (MPS)
  • 12.5.4. Enzyme Replacement Therapy for Pompe Disease
  • 12.5.5. Enzyme Replacement Therapy for Lysosomal Acid Lipase Deficiency
  • 12.5.6. Others
• 12.6. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Route of Administration, 2024 - 2031
  • 12.6.1. Oral Enzyme Replacement Therapy
  • 12.6.2. Injectable Enzyme Replacement Therapy
• 12.7. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Distribution Channel, 2024 - 2031
  • 12.7.1. Hospital Pharmacies
  • 12.7.2. Specialty Treatment Pharmacies
  • 12.7.3. Retail Pharmacies
• 12.8. Market Attractiveness Analysis

13. Competition Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. Market Structure
  • 13.2.1. Competition Intensity Mapping By Market
  • 13.2.2. Competition Dashboard
• 13.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 13.3.1. Sanofi Genzyme
    • 13.3.1.1. Overview
    • 13.3.1.2. Segments and Therapeutic Conditions
    • 13.3.1.3. Key Financials
    • 13.3.1.4. Market Developments
    • 13.3.1.5. Market Strategy
  • 13.3.2. Shire (now part of Takeda Pharmaceuticals)
  • 13.3.3. BioMarin Pharmaceutical Inc.
  • 13.3.4. Amicus Therapeutics
  • 13.3.5. Alexion Pharmaceuticals
  • 13.3.6. Ultragenyx Pharmaceutical Inc.
  • 13.3.7. Sarepta Therapeutics
  • 13.3.8. Biomarin
  • 13.3.9. Genzyme (now part of Sanofi)
  • 13.3.10. Takeda Pharmaceuticals
  • 13.3.11. Pfizer Inc.
  • 13.3.12. AbbVie Inc.
  • 13.3.13. Vertex Pharmaceuticals
  • 13.3.14. Sangamo Therapeutics
  • 13.3.15. Regeneron Pharmaceuticals Inc.
  • 13.3.16. Spark Therapeutics (now part of Roche)
  • 13.3.17. Orchard Therapeutics
  • 13.3.18. Novartis AG
  • 13.3.19. CSL Behring
  • 13.3.20. Audentes Therapeutics

14. Appendix

• 14.1. Research Methodology
• 14.2. Research Assumptions
• 14.3. Acronyms and Abbreviations

관련자료